Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
SSY Group ( (HK:2005) ) has provided an update.
SSY Group Limited has received approvals from China’s National Medical Products Administration for the production and registration of its Multiple Electrolytes, Sodium Acetate and Glucose Injection in 250ml and 500ml formats, as well as its Metoclopramide Hydrochloride Injection. Both products are classified as type 3 chemical drugs and have passed the country’s consistency evaluation, supporting their competitiveness in the regulated hospital market.
The electrolyte and glucose injection is indicated for replacing and maintaining water and electrolyte balance while providing energy when oral intake is not feasible, reinforcing SSY Group’s core infusion therapy portfolio. The Metoclopramide injection, used to prevent and treat various causes of nausea and vomiting and to assist certain diagnostic procedures, builds on the group’s earlier approval for its Metoclopramide bulk drug and is expected to broaden its injectable offerings and strengthen its position in China’s clinical treatment segment.
The most recent analyst rating on (HK:2005) stock is a Hold with a HK$3.00 price target. To see the full list of analyst forecasts on SSY Group stock, see the HK:2005 Stock Forecast page.
More about SSY Group
SSY Group Limited is a China-focused pharmaceutical group engaged in the development and production of intravenous infusion solutions and related injectable drugs. The company targets hospital and clinical markets with a portfolio of chemical drug preparations, including bulk drug ingredients and finished dosage forms approved by Chinese regulators.
Average Trading Volume: 9,118,374
Technical Sentiment Signal: Sell
Current Market Cap: HK$7.35B
See more insights into 2005 stock on TipRanks’ Stock Analysis page.